BCG Vaccine Mix for percutaneous use is named as an intervention in 4 current clinical trials in our USA register. None are recruiting at the moment. The most common phase is Phase EARLY_PHASE1. The lead sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The most-studied condition is HIV Infections.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
NCT03305341 · ClinicalTrials.gov ↗ · Covid19
|
Phase EARLY_PHASE1 | Active, closed | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | USA |
|
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563 · ClinicalTrials.gov ↗ · HPV Infection
|
Phase EARLY_PHASE1 | Active, closed | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | USA |
|
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
NCT07182838 · ClinicalTrials.gov ↗ · HIV Infections
|
Phase EARLY_PHASE1 | Active, closed | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | USA |
|
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
NCT02403505 · ClinicalTrials.gov ↗ · Rectal Cancer
|
Phase 1 | Active, closed | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA register name BCG Vaccine Mix for percutaneous use as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 4 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BCG Vaccine Mix for percutaneous use works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BCG Vaccine Mix for percutaneous use works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BCG Vaccine Mix for percutaneous use (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.